3654 results for «333»
3654 results
Percutaneous treatment of pure aortic regurgitation: a new indication
21 Sep 2023 – From AICT-AsiaPCR 2023
Analyse the case of an 83-year-old male patient with history of HT, parkinson's disease and minor stroke, who presented with worsening exertional SOB, LVEF 55-60 %, dilated LV, mild MR, and severe AR, and study the different options to treat aortic regurgitation.
Valve-in-valve - LIVE case
21 Sep 2023 – From AICT-AsiaPCR 2023
An 84-year-old man, with a history of 23 Carpentier-Edwards in 2004, PPM in 2013, AF on warfarin and impaired LV function (40 %), presented with severe symptomatic stenosis of the surgical bioprosthesis.
A 23 Navitor was implanted without predilatation and with post-dilatation under cerebral protection (Sentinel).
Closure was...
Calcified bifurcation lesion - LIVE case
22 Sep 2023 – From AICT-AsiaPCR 2023
A 59-year-old female patient with type 2 DM, dyslipidaemia, hypothyroidism and impaired LV function (39%) presented with multivessel disease. RCA PCI was performed 3 days ago.
The prox and mid LAD showed a severe calcified lesion including the diagonal. The lesion was prepared using a 1.25 Rotaglide™ ('single-person'...
Complex CTO - LIVE case
22 Sep 2023 – From AICT-AsiaPCR 2023
View the case of an 82-year-old man with history of CABG in 2003 (LIMA LAD, VG RCA, VG CX), PCIs on VG RCA in 2021, PCIs VG-CX in 2022, PPM in 2023 with preserved LV function, and follow the retrograde approach of calcified CX CTO using...
AICT-AsiaPCR 2023 Awards Ceremony
22 Sep 2023 – From AICT-AsiaPCR 2023
With a record number of abstracts and clinical cases submitted this year, the winners of these AICT-AsiaPCR 2023 awards have done an excellent job, as the selection process was extremely rigorous. Find out more about the finalists, their reactions and the works that led them to...
AICT-AsiaPCR 2023 Closing Ceremony
22 Sep 2023 – From AICT-AsiaPCR 2023
As AICT-AsiaPCR 2023 draws to a close, it's time to say thank you to the 950 participants and all those who helped make the conference a success, both on stage and behind the scenes.
Revolutionising coronary calcium treatment: unleashing the potential of intravascular lithotripsy
21 Sep 2023 – From AICT-AsiaPCR 2023
Over the last five years, we have learned that there is a new tool for treating calcium, the greatest enemy of interventional cardiology, which can take various forms: intravascular lithotripsy. In this session, look at how to master this technique in different scenarios, from eccentric calcified...
A hybrid approach in complex PCI: can DES and DCB be complementary?
21 Sep 2023 – From AICT-AsiaPCR 2023
Watch this case-based session to follow discussion about how to choose between DES & DCB, how both can be complementary in diffuse disease as well as in complex PCI, and how physiology and imaging can help guiding PCI, and follow a patient's treatment live.
Leave nothing behind: DCB-only PCI strategy - How DCB evidence has changed today's practice?
22 Sep 2023 – From AICT-AsiaPCR 2023
This session offers an opportunity to stay informed about the recent developments in the International DCB Consensus Group, gain insights into the latest clinical data and real-world experiences related to drug-coated balloon (DCB)-only PCI, understand the safety aspects of DCB in managing complex PCI cases, and...
Dynamx bioadaptor restores rotational motion and vessel stress reduction in new study
02 Jun 2022
Frequency and safety of bioprosthetic valve fracture in patients undergoing valve in valve TAVR for failed surgical valves using the SAPIEN 3/Ultra Valves: Insights from real-world data
19 Sep 2022
Michele Pighi provides his take on this trial which aimed to compare the safety and efficacy of VIV-TAVI with or without bioprosthetic valve fracture. It was presented by Santiago Garcia during the TCT Congress 2022.
Author
On-site computed tomography-derived fractional flow reserve to guide the management of patients with stable coronary artery disease: The TARGET randomized trial
05 Mar 2023
Mirvat Alasnag provides her take on this clinical trial presented by Yundai Chen at the American College of Cardiology Scientific Session (ACC.23/WCC).
Author
Elixir Medical completes enrollment in BIOADAPTOR randomized controlled trial of Dynamx Coronary Bioadaptor System
15 Feb 2022
TRISCEND II: Two-year outcomes of transcatheter tricuspid valve replacement for severe tricuspid regurgitation
31 Mar 2026
Jonathan Curio provides his take on TRISCEND II trial results presented by Vinod H. Thourani at ACC.26 in New Orleans.
Author
